PHILIPS IMAGE GUIDED THERAPY CORPORATION

PHILIPS IMAGE GUIDED THERAPY CORPORATION has been granted 225 US utility patents between 2020 and 2025, placing PHILIPS IMAGE GUIDED THERAPY CORPORATION at rank #1,809 across all assignees tracked by PlainPatent. This portfolio spans 26 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.5 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, PHILIPS IMAGE GUIDED THERAPY CORPORATION is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 61.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 225 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. PHILIPS IMAGE GUIDED THERAPY CORPORATION's 17.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 26 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark PHILIPS IMAGE GUIDED THERAPY CORPORATION against peers pursuing similar technology classes.